MetLife Investment Management
HRMY icon

MetLife Investment Management’s Harmony Biosciences HRMY Stock Holding History

MetLife Investment Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$967K Buy
26,556
+1,712
+7% +$54K ﹤0.01% 1544
2026
Q1 		$696K Sell
24,844
-224
-0.9% -$7.34K ﹤0.01% 1593
2025
Q4 		$938K Sell
25,068
-1,290
-5% -$42.4K ﹤0.01% 1469
2025
Q3 		$726K Hold
26,358
– – ﹤0.01% 1629
2025
Q2 		$833K Buy
26,358
+3,579
+16% +$115K ﹤0.01% 1405
2025
Q1 		$756K Sell
22,779
-348
-2% -$12.5K ﹤0.01% 1500
2024
Q4 		$796K Buy
23,127
+5,242
+29% +$180K ﹤0.01% 1537
2024
Q3 		$715K Sell
17,885
-1,397
-7% -$49.1K ﹤0.01% 1584
2024
Q2 		$582K Buy
19,282
+1,735
+10% +$52.2K ﹤0.01% 1642
2024
Q1 		$589K Hold
17,547
– – ﹤0.01% 1585
2023
Q4 		$567K Hold
17,547
– – ﹤0.01% 1612
2023
Q3 		$575K Hold
17,547
– – ﹤0.01% 1546
2023
Q2 		$617K Buy
17,547
+3,275
+23% +$113K ﹤0.01% 1561
2023
Q1 		$466K Hold
14,272
– – ﹤0.01% 1688
2022
Q4 		$786K Hold
14,272
– – 0.01% 1344
2022
Q3 		$632K Hold
14,272
– – 0.01% 1466
2022
Q2 		$696K Buy
14,272
+575
+4% +$25.9K 0.01% 1435
2022
Q1 		$666K Buy
13,697
+4,360
+47% +$178K ﹤0.01% 1599
2021
Q4 		$398K Hold
9,337
– – ﹤0.01% 1630
2021
Q3 		$358K Hold
9,337
– – ﹤0.01% 1721
2021
Q2 		$264K Buy
+9,337
New +$280K ﹤0.01% 1979

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MetLife Investment Management's HRMY Position: Q2 2026 in Review

MetLife Investment Management increased its Harmony Biosciences (HRMY) stake by 6.9% in Q2 2026, buying an estimated $54K and bringing the position to 26,556 shares worth $967K. The position accounts for ﹤0.01% of the portfolio, ranked #1544.

MetLife Investment Management first reported a position in HRMY in Q2 2021 and has held it in 21 quarters since. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • MetLife Investment Management held 26,556 shares of Harmony Biosciences worth $967K as of Q2 2026.
  • MetLife Investment Management bought 1,712 Harmony Biosciences shares in Q2 2026, an estimated $54K.
  • Harmony Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1544 holding.
  • MetLife Investment Management first reported a position in Harmony Biosciences in Q2 2021 and has held it in 21 quarters since.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.